LLY

1,067

+2.3%↑

JNJ

234.77

+1.5%↑

ABBV

216.92

+0.74%↑

UNH

387.76

+1.44%↑

AZN.UK

13,902

-1.08%↓

LLY

1,067

+2.3%↑

JNJ

234.77

+1.5%↑

ABBV

216.92

+0.74%↑

UNH

387.76

+1.44%↑

AZN.UK

13,902

-1.08%↓

LLY

1,067

+2.3%↑

JNJ

234.77

+1.5%↑

ABBV

216.92

+0.74%↑

UNH

387.76

+1.44%↑

AZN.UK

13,902

-1.08%↓

LLY

1,067

+2.3%↑

JNJ

234.77

+1.5%↑

ABBV

216.92

+0.74%↑

UNH

387.76

+1.44%↑

AZN.UK

13,902

-1.08%↓

LLY

1,067

+2.3%↑

JNJ

234.77

+1.5%↑

ABBV

216.92

+0.74%↑

UNH

387.76

+1.44%↑

AZN.UK

13,902

-1.08%↓

Home・Stock List・AstraZeneca PLC

AstraZeneca PLC

Open

SectorHealthcare

187.29 -1.47

Buy Sell

Overview

Share price change

24h

Current

Min

186.25

Max

189.72

Key metrics
By Trading Economics
Income	1.6B 3.9B
Sales	-215M 15B
P/E Sector Avg	27.887 49.701
EPS	1.29
Dividend yield	1.74
Profit margin	25.602
Employees	96,100
EBITDA	1.1B 5.7B

Recommendations
By TipRanks
Recommendations	Strong Buy
12 Months Forecast	+15.23% upside

Dividends
By Dow Jones
Dividend yield Sector Avg	1.74% 2.39%
Next Earnings	27 Jul 2026
Next Ex Dividend date	6 Aug 2026

Market Stats
By TradingEconomics
Market Cap	-3.5B 287B
Previous open	188.76
Previous close	187.29

News Sentiment

By Acuity

34%

66%

81 / 345 Healthcare

Technical Score

By Trading Central

Confidence

Strong Bearish Evidence

N/A / 69.55 Support & Resistance

AstraZeneca PLC Chart

Past performance is not a reliable indicator of future results.

Related News

29 Apr 2026, 16:28 UTC

Earnings

Correction to AstraZeneca Update

29 Apr 2026, 15:11 UTC

Earnings

AstraZeneca Plans U.K. Investment as Cancer Drugs Lift Revenue -- Update

29 Apr 2026, 06:31 UTC

Earnings

AstraZeneca Gets Revenue Boost From Cancer Drugs

21 May 2026, 11:06 UTC

Market Talk

AstraZeneca Set for Busy End of Year -- Market Talk

13 May 2026, 12:29 UTC

Market Talk

AstraZeneca Has Room to Grow in Heart Disease With Wainua -- Market Talk

13 May 2026, 11:54 UTC

Market Talk

AstraZeneca Has Credible Growth Path Beyond 2030 -- Market Talk

1 May 2026, 09:31 UTC

Market Talk

AstraZeneca Can Deal With Hit From FDA Cancer Drug Knockback -- Market Talk

29 Apr 2026, 10:29 UTC

Market Talk

Earnings

AstraZeneca Beats Expectations, But Focus Is on Busy Pipeline Ahead -- Market Talk

29 Apr 2026, 10:06 UTC

Market Talk

Earnings

AstraZeneca, GSK Results Fail to Impress Market -- Market Talk

29 Apr 2026, 09:53 UTC

Market Talk

Earnings

AstraZeneca Seems in Fine Health -- Market Talk

29 Apr 2026, 06:05 UTC

Earnings

AstraZeneca Says It Remains on Track to Achieve Ambition for 2030, Beyond

29 Apr 2026, 06:04 UTC

Earnings

AstraZeneca 1Q Ultomiris Revenue $1.27B, Up 18% at Constant Currency

29 Apr 2026, 06:04 UTC

Earnings

AstraZeneca 1Q Farxiga Revenue $2.19B, Down 2% at Constant Currency

29 Apr 2026, 06:03 UTC

Earnings

AstraZeneca 1Q Imfinzi Revenue $1.69B, Up 30% at Constant Currency

29 Apr 2026, 06:03 UTC

Earnings

AstraZeneca 1Q Tagrisso Revenue $1.83B, Up 5% at Constant Currency

29 Apr 2026, 06:02 UTC

Earnings

Analysts Saw AstraZeneca 1Q Core EPS at $2.54

29 Apr 2026, 06:01 UTC

Earnings

Analysts Saw AstraZeneca 1Q Revenue at $14.94B

29 Apr 2026, 06:01 UTC

Earnings

AstraZeneca Backs 2026 View

29 Apr 2026, 06:00 UTC

Earnings

AstraZeneca PLC 1Q Adj EPS $2.58

29 Apr 2026, 06:00 UTC

Earnings

AstraZeneca PLC 1Q Rev $15.29B

29 Apr 2026, 06:00 UTC

Earnings

AstraZeneca PLC 1Q Pretax Pft $3.91B

29 Apr 2026, 06:00 UTC

Earnings

AstraZeneca PLC 1Q Oper Pft $4.25B

29 Apr 2026, 06:00 UTC

Earnings

AstraZeneca PLC 1Q Net Pft $3.08B

29 Apr 2026, 06:00 UTC

Earnings

AstraZeneca PLC 1Q EPS $1.97

27 Apr 2026, 10:48 UTC

Market Talk

AstraZeneca Likely Unaffected by Partner Daiichi Sankyo's Supply Review -- Market Talk

10 Apr 2026, 11:57 UTC

Market Talk

AstraZeneca Likely to Increase Spending to Prepare for New Launches -- Market Talk

10 Apr 2026, 10:26 UTC

Market Talk

Earnings

AstraZeneca Expected to Reiterate Full-Year Guidance -- Market Talk

2 Apr 2026, 09:16 UTC

Market Talk

AstraZeneca Liver Cancer Trial Could Help Imfinzi Peak Sales Beat Views -- Market Talk

27 Mar 2026, 10:40 UTC

Market Talk

AstraZeneca Hits Goal in Lung Disease Where Rivals Missed -- Market Talk

27 Mar 2026, 10:17 UTC

Market Talk

AstraZeneca Lung Disease Trial Adds Building Block to 2030 Target -- Market Talk

Peer Comparison

Price change

AstraZeneca PLC Forecast

Price Target

By TipRanks

15.23% upside

12 Months Forecast

Average 216.011 USD 15.23%

High 249.911 USD

Low 151.828 USD

Based on 15 Wall Street analysts offering 12 month price targets forAstraZeneca PLC - Dist in the last 3 months.

Rating Consensus

By TipRanks

Strong Buy

15 ratings

Buy

Hold

Sell

Based on 15 analysts giving stock ratings to AstraZeneca PLC - Dist in the past 3 months.

Technical Score

By Trading Central

N/A / 69.55Support & Resistance

Recent bearish events outweigh bullish events.

Sentiment

By Acuity

81 / 345 Healthcare

Financials

Selling and administration expenses

Operating expenses

Pre-tax profit

Sales

Cost of sales

Gross profit on sales

Interest expense on debt

EBITDA

Operating profit

About AstraZeneca PLC

AstraZeneca PLC, a biopharmaceutical company, focuses on the discovery, development, manufacture, and commercialization of prescription medicines. The company's marketed products include Tagrisso, Imfinzi, Lynparza, Calquence, Enhertu, Orpathys, Truqap, Zoladex, Faslodex, Farxiga, Brilinta, Lokelma, Roxadustat, Andexxa, Crestor, Seloken, Onglyza, Bydureon, Fasenra, Breztri, Symbicort, Saphnelo, Tezspire, Pulmicort, Bevespi, and Daliresp for cardiovascular, renal, metabolism, and oncology. Its marketed products also comprise Vaxzevria, Beyfortus, Synagis, FluMist, Soliris, Ultomiris, Strensiq, Koselugo, and Kanuma for covid-19 and rare disease. The company serves primary care and specialty care physicians through distributors and local representative offices in the United Kingdom, rest of Europe, the Americas, Asia, Africa, and Australasia. It has a collaboration agreement with Neurimmune AG to develop and commercialize NI006; BenevolentAI for drug discovery for systemic lupus erythematosus; Lunit for developing AI-Powered Digital Pathology Risk Assessment Tools for NSCLC; and Absci Corporation for AI-driven drug discovery against an oncology target. The company was formerly known as Zeneca Group PLC and changed its name to AstraZeneca PLC in April 1999. AstraZeneca PLC was incorporated in 1992 and is headquartered in Cambridge, the United Kingdom.